Navigation Links
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Date:6/10/2008

Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance

and total sleep time compared to placebo

BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were administered a Selective Serotonin Reuptake Inhibitor (SSRI) for depression. Ambien CR also improved sleep-related next-day functioning measures. This data was presented at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

Thomas Roth, PhD, director of the Sleep Disorders and Research Center at Henry Ford Hospital, states, "The results of this study demonstrate that Ambien CR can be considered a viable treatment option for the insomnia MDD patients experience and help them get the good night's sleep they need to improve their next-day functioning."

Ambien CR Improved Sleep Quality and Sleep Impact on Daily Activities in MDD Patients

Total sleep time was increased in the Ambien CR group throughout the study. At Week eight, patients reporting sleeping an average of 101 minutes more than baseline compared to placebo-treated patients who reported sleeping an average 64 minutes more (P<0.0001). On average, Ambien CR-treated patients reported falling asleep sooner and exhibited improved sleep maintenance based upon fewer nighttime awakenings and decreased wake time after sleep onset compared to placebo-treated patients (P<0.0001). In addition, patients reported improvements in secondary measures related to daytime functioning, including morning energy, morning concentration and sleep impact on daily activities.

Treatment-emergent adverse events occurred in 72.9 percent of the patients treated wi
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
4. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
5. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
6. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Feb. 9, 2011 GeoVax Labs, Inc. (OTC Bulletin ... develops and tests innovative HIV/AIDS vaccines, announced today the ... Alabama Vaccine Research Clinic (AVRC) of the University of ... therapeutic vaccine trial. Although the GeoVax vaccines are currently ...
... The Covaris® LE220™ high performance ultra-sonicator has received ... at the LabAutomation 2011 conference in Palm Springs ... laboratory automation conference and exhibition, bringing science, technology, and ... LabAutomation are evaluated by a team of industry experts. ...
Cached Medicine Technology:GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 2GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 3Covaris Receives the Society for Laboratory Automation and Screening (SLAS) New Product Award at LabAutomation 2011 2
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... use has been found to contribute to gum disease, apart ... to have. , In a group of more than 900 ... since age 18 was found to be responsible for more ... ages 26 and 32, according to a study published Feb. ...
... finds, , , TUESDAY, Feb. 5 (HealthDay News) -- Pot smokers ... do, such as an increased risk of heart disease, but ... destroy gum tissue. , In the Feb. 6 issue ... researchers reported that heavy marijuana users have as much as ...
... thousands of studies ... benefits of therapeutic lasers, FORT COLLINS, Colo., Feb. ... of the company, and the availability of,professional-grade therapeutic laser ... hand therapists, and more),as well as consumer-grade therapeutic laser ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it will ... will be held February 11-13, 2008 at,the Grand Hyatt ... President and Chief Financial Officer of HMS,Holdings Corp., will ... A live broadcast of the Company,s presentation can ...
... SAFE IN THE SUN, ... CAMPAIGN, ... of the L,Oreal Group, announced that they have granted the,Women,s Dermatologic Society ... in the Sun campaign, effective April,2008. The WDS educational outreach campaign focuses ...
... high amounts of whole grains may help achieve significant ... diseases such as diabetes and cardiovascular disease, according to ... and the College of Medicine., "Consumption of whole grains ... lower blood pressure," said co-author Penny Kris-Etherton, distinguished professor ...
Cached Medicine News:Health News:Marijuana Bad for the Gums 2Health News:Marijuana Bad for the Gums 3Health News:Integrated Laser Therapies Launches, Offers Low-power, Therapeutic Laser Devices and Training for Therapists and Consumers 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 3Health News:Whole grain diets lower risk of chronic disease 2Health News:Whole grain diets lower risk of chronic disease 3
The original, and now classic, Bard mesh sheet can be tailored perioperatively and customized to any unique situation. Bard mesh sheets are available in seven convenient sizes....
... is constructed of Bard polypropylene mesh, the ... 40 years. Developed with the world renowned ... Mesh takes the guesswork out of sizing ... performs a Lichtenstein inguinal hernia repair procedure.,Its ...
... is a minimally invasive, tension-free technique that ... cm incision and requires minimal suturing. It ... open, anterior approach that can be completed ... patch is a self-expanding polypropylene patch that ...
... The Bard PerFix plug technique, recommended ... and recurrent indirect and direct inguinal ... conventional suture technique, requiring less overall ... complete tension-free repair technique. The result ...
Medicine Products: